European biopharmas saw a huge surge in new funding in the second quarter of 2024, raising a collective $4.1 billion, compared to $1.9 billion in the same period of 2023. With the IPO market in Europe still virtually non-existent, $1.45 billion of this was venture capital, while $2.64 billion was raised in follow-on funding.
Nuala Moran is a science journalist and staff writer for Bioworld co. With a focus on the pharmaceutical industry and biotechnology, Nuala covers a wide range of topics including drug development, gene therapy, regulatory challenges, and advancements in cancer research. Her articles provide in-depth analysis and insights into the latest developments in the field.